Is human papillomavirus (HPV)-associated squamous cell carcinoma of the base of the tongue significant in management?

Yes, HPV Status is Critically Significant in Management of Base of Tongue Squamous Cell Carcinoma

HPV-associated squamous cell carcinoma of the base of tongue fundamentally alters treatment planning, prognostic stratification, and surveillance strategies, making HPV testing mandatory for all oropharyngeal cancers including base of tongue lesions. 1

Why HPV Status Matters

Prognostic Implications

HPV-positive base of tongue cancers demonstrate markedly superior survival compared to HPV-negative disease. Research shows that HPV-positive base of tongue tumors have significantly better disease-specific and overall survival 2. This prognostic advantage is so substantial that the AJCC 8th edition created separate staging systems for HPV-positive versus HPV-negative oropharyngeal cancers 1.

Treatment Selection Impact

For Early Stage Disease (T1-T2):

• HPV-positive patients may be candidates for transoral robotic surgery (TORS) with bilateral neck dissection, as occult contralateral nodal disease occurs in 21.4% of cases 3, 4
• For base of tongue tumors specifically, bilateral neck dissection is recommended due to midline location and contralateral spread risk 4
• Despite better prognosis, current guidelines mandate that treatment intensity should NOT be reduced based on HPV status alone outside clinical trials 1

For Locally Advanced Disease:

• Standard treatment remains platinum-based concurrent chemoradiation (70 Gy with cisplatin 100 mg/m² on days 1,22,43) regardless of HPV status 1
• The treatment strategy for HPV-positive disease should be the same as HPV-negative disease in routine practice 1

Diagnostic Workup Requirements

Mandatory Testing Protocol:

1. p16 immunohistochemistry as initial screening (≥70% nuclear and cytoplasmic staining = positive) 5
2. HPV-specific testing (HR-HPV DNA or E6/E7 mRNA) to confirm true HPV-driven disease, especially for:
   • Base of tongue tumors (higher false-positive p16 rates)
   • Tumors with keratinizing morphology
   • Unknown primary presentations 5

Radiation Planning Considerations

For well-lateralized tonsillar cancers, unilateral radiotherapy may be appropriate (T1-T2, N0-N1, no soft palate or base of tongue involvement) 6. However, base of tongue involvement specifically excludes patients from unilateral treatment due to bilateral lymphatic drainage patterns 6.

Adjuvant Therapy Decisions

High-risk features requiring postoperative chemoradiation (regardless of HPV status):

• Positive surgical margins (R1)
• Extranodal extension (ENE) >1 mm
• ≥5 positive lymph nodes 4

Intermediate-risk features requiring radiation alone:

• Perineural invasion
• Lymphovascular invasion
• Close margins (<5 mm)
• pT3-T4a tumors 4

Recurrent/Metastatic Disease

For platinum-refractory recurrent/metastatic disease:

• Nivolumab improves OS (7.5 vs 5.1 months) regardless of HPV status 1
• Pembrolizumab (for PD-L1 CPS ≥1) shows benefit, with HPV-positive tumors generally having higher response rates 7, 1

Critical Pitfalls to Avoid

1. Do not de-escalate treatment based solely on HPV-positive status outside clinical trials—this remains investigational 1, 8

2. Do not rely on p16 alone for base of tongue tumors—confirm with HPV-specific testing to avoid false positives from non-HPV causes of p16 overexpression 5

3. Do not perform unilateral neck treatment for base of tongue primaries—bilateral drainage mandates bilateral neck management 6, 3

4. Do not skip contralateral neck evaluation in surgical candidates—21.4% harbor occult contralateral disease even when clinically N0 3

5. Do not delay adjuvant therapy—postoperative radiation/chemoradiation should begin within 6-7 weeks of surgery 1

Surveillance Implications

HPV-positive status enables:

• Potential use of circulating tumor HPV DNA (ctDNA) for surveillance (investigational) 4
• More confident observation of pathologically negative contralateral necks after bilateral dissection 3
• Understanding that most recurrences occur within 2 years, with continued second primary risk of 2-4% annually 1

Bottom line: HPV status is not just prognostically significant—it is diagnostically essential, influences surgical extent (particularly bilateral neck management for base of tongue), guides immunotherapy selection in recurrent disease, and enables emerging precision medicine approaches, while current standard treatment intensity remains unchanged pending de-escalation trial results.